FDA approves Merck combination cholesterol lowering pill

Fri May 3, 2013 3:44pm EDT

Related Topics

(Reuters) - The U.S. Food and Drug Administration approved a Merck & Co cholesterol lowering pill that combines a generic version of Pfizer Inc's Lipitor with its own Zetia, Merck said on Friday.

The new combination drug will be sold under the brand name Liptruzet and will begin shipping to wholesalers next week, the company said.

Merck already sells a two-drug cholesterol fighter called Vytorin that combines Zetia, known chemically as ezetimibe, with Merck's older LDL lowering medicine Zocor. Lipitor, known chemically as atorvastatin, is considered to a more powerful statin than Zocor.

Vytorin, which had sales of $1.75 billion in 2012, is currently undergoing a long-term trial to prove that it can reduce heart attacks and strokes better than Zocor (simvastatin) alone. While results of that study should definitively determine the value of Zetia to patients, the drug on its own rang up sales of $2.67 billion in 2012.

"No incremental benefit of Liptruzet on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established," Merck said.

The new drug will be available in four doses, combining 10 milligrams of Zetia with either 10, 20, 40 or 80mg of atorvastatin.

(Reporting by Bill Berkrot; editing by Sofina Mirza-Reid)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
AmherstRPh wrote:
THIS is the real waste in the USA health care system. Merck combining a product available generically with their $2B product Zetia which has no demonstrated effect on cardiovascular outcomes. Just so they can charge 50x what it’s worth. It has no benefit versus atorvastatin alone.

May 03, 2013 5:27pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.